Journals / Retina-Vitreus / 2019 / Cilt: 28 - Sayı: 1

Is There Aggravating Effect of Hyperbaric Oxygen Therapy on Diabetic Retinopathy and Macular Edema?

Hiperbarik Oksijen Tedavisi Sonrası Diyabetik Retinopatide İlerleme ve Maküla Ödeminde Artış Olabilir mi?

Pages
94–99
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that this condition should be addressed in all patients with elevated VEGF levels, such as DR.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 54-years-old diabetic patient was referred to our clinic for fundus examination.
📊
Key Findings & Data:The best corrected visual acuity(BCVA) with Snel- len’s chart was 0,3; 0,5 in the right and left eye.
💡
Conclusion & Impact:We believe that this condition should be addressed in all patients with elevated VEGF levels, such as DR.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 54-years-old diabetic patient was referred to our clinic for fundus examination. The best corrected visual acuity(BCVA) with Snel- len’s chart was 0,3; 0,5 in the right and left eye. In the fundus examination, moderate non-proliferative diabetic retinopathy(DR) sig- ns and diabetic macular oedema(DME) were detected in both eyes. FFA was planned. The increase in macular thickness(CMT) of both eyes, DME, serous macular detachment were shown by OCT. Intravitreal anti-VEGF injections were recommended at least 3 times 1 month apart for both eyes. However, because of the patient’s diabetic foot, we were not able to treat the patient and he rece- ived a month of hyperbaric oxygen therapy(HBOT). The patient again applied, indicating that there was a rapid vision decrease in his both eyes just at the 10 th day after the end of HBOT. The BCVA was 0,1; 0,05 in the right and left eye with Snellen’s chart. Inc- rease in DME, serous macular detachment in both eyes, and optic disc neovascularization (NVD) in the left eye, was detected. This progression may be due to the patient’s poorly controlled diabetes regulation and the lack of intravitreal treatment. However, visual acuity decrease not observed during HBOT but observed just at the 10 th day after the end of treatment, and the development of NVD needed questio- ning the situation. We think that the sudden drop in oxygen saturation after the end of HBOT may have contributed to this situation. We believe that this condition should be addressed in all patients with elevated VEGF levels, such as DR.

Özet

Elli dört yaşında diyabetik hasta polikliniğimize endokrin bölümünden göz dibi muayenesi için yönlendirildi. Muayenesinde en iyi düzeltilmiş görme keskinliği (EİDGK) Snellen eşeli ile sağ gözde 0,3 sol gözde 0,5 olup, göz tansiyonları ve biyomikroskopik muayenesi doğaldı. Fundus muayenesinde her iki gözde orta şiddette proliferatif olmayan diyabetik retinopati bulguları ve diyabetik makula ödemi tespit edildi. Hastaya fundus fl oresein anjiografi (FFA) çekilmesi planlandı. Hastanın çekilen optik kohorens tomografi sinde(OKT) her iki gözde makula kalınlığının artmış, kistoid makula ödemi ve seröz makula dekolmanı mevcuttu. Hastaya her iki göze 3 kez 1 ay ara ile intravitreal anti-VEGF(vasküler endotelyal growth faktör) enjeksiyonu önerildi. Ancak hasta diyabetik ayak nedeniyle önerdiğimiz anti-VEGF tedaviye gelemeyerek bir ay hiperbarik oksijen tedavisi(HBOT) aldı. Hasta HBOT bittikten 10 gün sonra görmesinde hızlı bir düşme olduğunu belirterek polikliniğimize tekrar başvurdu. Muayenesinde görmeleri Snellen eşeli ile sağ gözde 0,1 sol gözde 0,05 olup, her iki gözde makula ödeminde, seröz makula dekolmanında artış ve sol gözde optik disk neovaskülarizasyonu (NVD) gelişerek bu gözün proliferatif faza geçtiği saptandı. Bu ilerleme hastanın kötü giden diyabet regülasyonu ve intravitreal tedavisini alamaması nedeniyle gerçekleşmiş olabilir. Ancak görmede azalmanın HBOT sırasında değil ama tedavi bitiminden 10 gün sonra görülmesi ve NVD’nin hızlı gelişimi bu durumu sorgulamamıza neden oldu. HBOT bittikten sonra ani oksijen saturasyonu düşmesinin bu duruma katkı sağlamış olabileceği düşüncesindeyiz. HBO tedavisine gön- derilen diyabetik hastaların HBOT bitiminden hemen sonra oftalmolojik muayeneden geçirilerek fundus muayenelerinin sıkı takip edilmesi gerektiğini düşünüyoruz. Diyabetik retinopatide olduğu gibi vitreusta artmış VEGF düzeyleri olan tüm hastalarda bu durumun irdelenmesi gerektiği kanaatindeyiz.

🔖

Cite This Article

AKKAYA, S., KAPLAN, F. B. (2019). Is There Aggravating Effect of Hyperbaric Oxygen Therapy on Diabetic Retinopathy and Macular Edema?. Retina-Vitreus, Cilt: 28 - Sayı: 1, 94–99. https://ajindex.com/articles/304815

References (12)

  1. Stephen R. Thom. Hyperbaric oxygen–its mechanisms and effi ca- cy. Plast.Reconstr. Surg. 2011; 127(Suppl.):131-141.
  2. Skeik N, Porten BR, Isaacson E, Seong J, Klosterman DL, Gar- berich RF et al. Hyperbaric oxygen treatment outcome for dif- ferent indications from a single center. Ann Vasc Surg. 2015 Feb;29(2):206-14.
  3. Heyboer M, Sharma D, Santiago W, McCulloch N. Hyperba- ric Oxygen Therapy: Side Effects Defi ned and Quantifi ed.Adv Wound Care (New Rochelle). 2017 Jun 1; 6(6): 210–224.Signifi - cance: Hyperbaric oxygen therapy (HBOT) is an important Löndahl M, Landin-Olsson M, Katzman P. Hyperbaric oxygen therapy improves health-related quality of life in patients with dia- betes and chronic foot ulcer. Diabet Med. 2011 Feb;28(2):186-90.
  4. Sheikh AY, Gibson JJ, Rollins MD, Hopf HW, Hussain Z, Hunt TK. Effect of hyperoxia on vascular endothelial growth factor le- vels in a wound model. Arch Surg. 2000 Nov;135(11):1293-7.
  5. Kang TS, Gorti GK, Quan SY, Ho M, Koch RJ. Effect of hyperba- ric oxygen on the growth factor profi le of fi broblasts. Arch Facial Plast Surg. 2004 Jan-Feb;6(1):31-5.
  6. Lin S, Shyu KG, Lee CC, Wang BW, Chang CC, Liu YC, et al. Hyperbaric oxygen selectively induces angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2002;296(3):710-5.
  7. Kimmel HM, Grant A, Ditata J. The Presence of Oxygen in Wound Healing. Wounds. 2016 Aug;28(8):264-70.
  8. Poff AM, Kernagis D, D’Agostino DP. Hyperbaric Environment: Oxygen and Cellular Damage versus Protection. Compr Physiol. 2016 Dec 6;7(1):213-234.
  9. Cope A, Eggert JV, O’Brein E. Retinal artery occlusion: visual outcome after treatment with hyperbaric oxygen. Diving Hyperb Med 2011;41(3):135-8
  10. Evanger K, Pierscionek BK, Vaagbø G, Thorsen E, Haugen OH. Myopic Shift during Hyperbaric Oxygenation Attributed to Lens Index Changes. Optom Vis Sci. 2015 Nov;92(11):1076-84. McMonnies CW. Hyperbaric oxygen therapy and the possibility of ocular complications or contraindications. Clin Exp Optom. 2015 Mar;98(2):122-5.
  11. Lajko M, Cardona HJ, Taylor JM, Shah RS, Farrow KN, Faw- zi AA. Hyperoxia-Induced Proliferative Retinopathy: Early In-terruption of Retinal Vascular Development with Severe and Irreversible Neurovascular Disruption.PLoS One. 2016 Nov 18;11(11):e0166886. doi: 10.1371 Yonekawa Y, Hypes SM, Abbey AM, Williams GA, Wolfe JD. Exacerbation of macular oedema associated with hyperbaric oxy- gen therapy.Clin Exp Ophthalmol. 2016 Sep;44(7):625-626.
  12. TranV, SmartD. Proliferative retinopathy duri